Akeso, Inc., a leading biopharmaceutical company, announced that the first patient has been successfully enrolled in the registration phase III clinical trial (AK112-312/HARMONi-GI6) of ivonescimab in ...

A massive global study has ranked the best and safest treatments for chronic hives when antihistamines fall short. The findings provide a clear treatment roadmap for both patients and clinicians ...

He emphasised that children referred for advanced treatment must be consistently followed up, ensuring their treatment is completed without delay.

Nashville-Davidson, June 30, 2025 (GLOBE NEWSWIRE) -- NASHVILLE, Tenn. — Cutting Edge Foot and Ankle Clinic has introduced a new treatment for onychomycosis, more commonly known as toenail ...

Nashville-Davidson, June 30, 2025 (GLOBE NEWSWIRE) -- NASHVILLE, Tenn. — Cutting Edge Foot and Ankle Clinic has introduced a new treatment for onychomycosis, more commonly known as toenail fungus. The ...

Colorectal cancer (CRC) is the second most common cause of death from cancer in the United States (US) and the most prevalent malignant tumor worldwide.

However, approximately half of the patients who receive the current standard first-line treatment for advanced triple-negative breast cancer do not survive long enough to receive a second line of ...

My new husband gave me a contract and told me to ‘sign here’ — but I refused. It was the best decision of my life. ‘The Best You Can' Review: Kyra Sedgwick and Kevin Bacon Bring Warmth and ...

Incyte announces FDA approval of Zynyz® (retifanlimab-dlwr) making it the first and only approved first-line treatment for advanced anal cancer patients in the United States. News release. Incyte.

Intermountain Health cancer experts say the groundbreaking treatment marks a significant advancement in the fight against advanced melanoma, offering a new option for patients with limited ...

AMD drops 4nm orders with Samsung due to low yield rates and US tariffs, turns to TSMC in Arizona for chip production. Trump's tariff policies also prompt Nvidia and Apple to use the facility. Q1 ...

KEYTRUDA® (pembrolizumab) as Perioperative Treatment With Standard of Care (SOC) Adjuvant Therapy Significantly Improved Event-Free Survival Compared to SOC Alone in Patients With Resectable Locally ...